Clinical trials: Thyroid Cancer Patients
Thyroid Carcinoma, Hypothyroidism
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
The purpose of this study is to evaluate whether taking thyroid hormone medication with beverages other than water, decreases absorption of the medication by the intestine.
- Trial name
- NCT01707056
- Testing
- Black Coffee, Coffee with Milk, Black Tea
- Where
- 3 sites in United States
- Sponsor
- Medstar Health Research Institute
Thyroid Cancer
Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer
The goal of this study is to learn if a decision aid (DA) website helps people with thyroid cancer make informed decisions about radioactive iodine (RAI) treatment.
- Trial name
- NCT06980103
- Testing
- Decision Aid, Usual Care
- Where
- 3 sites in United States
- Volunteers
- 408 people
- Sponsor
- Georgetown University
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first…
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma
- Trial name
- NCT02465060
- Testing
- Adavosertib, Afatinib, Afatinib Dimaleate
- Where
- 1,410 sites in United States, Guam and 1 more
- Volunteers
- 6,452 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer
The purpose of this study is to find out whether people who have had thyroid cancer develop resistance to treatment with thyroid hormones after having received high doses of thyroid drugs for many years.
- Trial name
- NCT04868045
- Testing
- Thyrotropin Releasing Hormone (TRH), levothyroxine, Hypothyroidism QOL questionnaire
- Sponsor
- Memorial Sloan Kettering Cancer Center
Thyroid Cancer, Prostate Cancer
Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
- Conditions
- Thyroid Cancer, Prostate Cancer, Neuroendocrine Tumors, SSTR Positive Tumors
- Trial name
- BCB RIV (NCT04104529)
- Testing
- Biological collection, tumor collection
- Where
- 4 sites in France
- Volunteers
- 350 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Tumor Pathway Activations Inhibited by Dovitinib
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further…
- Trial name
- SIGNATURE (NCT01831726)
- Testing
- Dovitinib (TKI258)
- Where
- 49 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Haematological Malignancy, Melanoma
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma.
- Conditions
- Haematological Malignancy, Melanoma, Thyroid Cancer, Papillary, Ovarian Neoplasms
- Trial name
- DETERMINE (NCT05768178)
- Testing
- Vemurafenib, Cobimetinib
- Where
- 16 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
This phase II trial studies how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug…
- Conditions
- Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Refractory Differentiated Thyroid Gland Carcinoma
- Trial name
- NCT03914300
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma
Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
This phase II trial tests how well vemurafenib and cobimetinib work in treating patients with high risk differentiated thyroid carcinoma with BRAFV600E mutation, in preparation for radioactive iodine therapy.
- Conditions
- Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma, Thyroid Gland Papillary Carcinoma
- Trial name
- NCT06440850
- Testing
- Biospecimen Collection, Cobimetinib, Computed Tomography
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- City of Hope Medical Center
Genomics, Thyroid Cancer
Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk Stratification and Post-Treatment Surveillance in Fresh Thyroid Cancer Patients
Thyroid cancer is the most common endocrine malignancy, and although differentiated thyroid cancer (DTC) generally confers favorable outcomes, 10-20% of patients still face substantial postoperative risks, including local…
- Conditions
- Genomics, Thyroid Cancer, NGS
- Trial name
- NCT07532356
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Thyroid Cancer, Thyroid Neoplasms
IoN- Is Ablative Radio-iodine Necessary for Low Risk Differentiated Thyroid Cancer Patients
IoN is a phase II/III trial that will look to ascertain whether or not radio-iodine ablation is necessary for low risk differentiated thyroid cancer patients.
- Trial name
- IoN (NCT01398085)
- Testing
- I131 1.1 GBq, No Radioactive iodine (No-RAI) ablation
- Where
- 36 sites in United Kingdom
- Volunteers
- 504 people
- Sponsor
- University College, London
Thyroid Cancer
PECS II Block and Single Port Robot-assisted Transaxillary Thyroidectomy
The da Vinci robotic system was developed to improve both operative maneuverability (through multi-articulated instruments) and the surgical view (via a three-dimensional camera).
- Trial name
- NCT06101043
- Testing
- Pectoral nerve block
- Volunteers
- 76 people
- Sponsor
- Min Suk Chae
Head and Neck Cancer
Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01164176
- Testing
- everolimus, laboratory biomarker analysis
- Where
- 7 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Head and Neck Cancer, Lung Cancer
Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00021333
- Testing
- filgrastim, cisplatin, paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 29 people
- Sponsor
- Fox Chase Cancer Center
Thyroid Cancer, Hyperthyroidism
A Brief Video Intervention to Improve Patient Outcomes Following Radioiodine Treatment
This study will test the impact of a short video intervention for people who are receiving radioiodine treatment for thyroid conditions (such as hyperthyroidism or thyroid cancer).
- Conditions
- Thyroid Cancer, Hyperthyroidism, Radioiodine Treatment
- Trial name
- NCT07405320
- Testing
- Intervention Video, Control Video
- Volunteers
- 80 people
- Sponsor
- University of Auckland, New Zealand
Papillary Thyroid Carcinoma, Recurrence Free Survival
Clinicopathological Predictors of Recurrence in Papillary Thyroid Carcinoma
The goal of this observational study is to identify demographic and clinicopathological factors associated with disease recurrence in adults with histologically confirmed papillary thyroid carcinoma (PTC) who achieved an initial…
- Trial name
- NCT07695974
- Where
- Italy
- Volunteers
- 1,113 people
- Sponsor
- University of Roma La Sapienza
Leukaemia (Chronic)
What is the Impact of TKI on Thyroid Function in CML Patients?
Evaluation of the impact of various TKI on thyroid function in patients diagnosed with cml
- Trial name
- NCT07200882
- Volunteers
- 76 people
- Sponsor
- Assiut University
Thyroid Cancer
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
The study will include 50 patients newly diagnosed with low-risk thyroid cancer ranging from 18-80 years of age. After scheduling their surgeon visit, the investigators will enroll patients and measure their intended treatment…
- Trial name
- NCT06073223
- Testing
- Usual Care, CQUPLE
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center